Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1996 Nov;61(5):515–517. doi: 10.1136/jnnp.61.5.515

Interferon-gamma activated calcium influx in peripheral blood lymphocytes from patients with primary and secondary progressive multiple sclerosis.

G Martino 1, E Brambilla 1, M Filippi 1, V Martinelli 1, B Colombo 1, M Rodegher 1, G Comi 1, L M Grimaldi 1
PMCID: PMC1074051  PMID: 8937348

Abstract

Interferon-gamma (IFN-gamma) contributes to the early events leading to T cell activation in relapsing-remitting (RR) multiple sclerosis (MS) by activating a transplasmalemma calcium influx, the detection of which is closely associated with clinical and MRI evidence of disease activity. The appearance of this influx represents one of the earliest peripheral events in the pathogenesis of RRMS. It is still questioned whether the same immune mediated mechanisms also operate in primary progressive (PP)MS. Fluorimetric evidence of the IFN-gamma activated calcium influx was sought in 16 patients with PPMS and 39 patients with secondary progressive (SP)MS. To compare peripheral versus CNS evidence of immune activation 11 of the patients with PPMS and 27 of the patients with SPMS underwent gadolinium enhanced brain MRI. The IFN-gamma activated influx was detected in peripheral blood lymphocytes from eight of 16 (50%) patients with PPMS, and 20 of 39 (51%) patients with SPMS, a frequency similar to that previously reported in patients with RRMS during phases of disease stability. Gadolinium enhancing brain MRI lesions were found in only one of 11 (9%) patients with PPMS and 12 of 27 (41%) with SPMS. Our study shows that peripheral blood lymphocytes from patients with PPMS and patients with SPMS express with the same frequency as patients with RRMS, an IFN-gamma dependent intracellular process leading to T cell activation able to trigger disease activity.

Full text

PDF
515

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Filippi M., Campi A., Martinelli V., Colombo B., Yousry T., Canal N., Scotti G., Comi G. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 1995 Nov;59(5):540–544. doi: 10.1136/jnnp.59.5.540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Kurtzke J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444–1452. doi: 10.1212/wnl.33.11.1444. [DOI] [PubMed] [Google Scholar]
  3. Martin R., McFarland H. F., McFarlin D. E. Immunological aspects of demyelinating diseases. Annu Rev Immunol. 1992;10:153–187. doi: 10.1146/annurev.iy.10.040192.001101. [DOI] [PubMed] [Google Scholar]
  4. Martino G., Clementi E., Brambilla E., Moiola L., Comi G., Meldolesi J., Grimaldi L. M. Gamma interferon activates a previously undescribed Ca2+ influx in T lymphocytes from patients with multiple sclerosis. Proc Natl Acad Sci U S A. 1994 May 24;91(11):4825–4829. doi: 10.1073/pnas.91.11.4825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Martino G., Filippi M., Martinelli V., Brambilla E., Comi G., Grimaldi L. M. Clinical and radiologic correlates of a novel T lymphocyte gamma-interferon-activated Ca2+ influx in patients with relapsing-remitting multiple sclerosis. Neurology. 1996 May;46(5):1416–1421. doi: 10.1212/wnl.46.5.1416. [DOI] [PubMed] [Google Scholar]
  6. Martino G., Moiola L., Brambilla E., Clementi E., Comi G., Grimaldi L. M. Interferon-gamma induces T lymphocyte proliferation in multiple sclerosis via a Ca(2+)-dependent mechanism. J Neuroimmunol. 1995 Nov;62(2):169–176. doi: 10.1016/0165-5728(95)00117-2. [DOI] [PubMed] [Google Scholar]
  7. Minderhoud J. M. On the pathogenesis of multiple sclerosis. A revised model of the cause(s) of multiple sclerosis, especially based on epidemiological data. Clin Neurol Neurosurg. 1994 May;96(2):135–142. doi: 10.1016/0303-8467(94)90047-7. [DOI] [PubMed] [Google Scholar]
  8. Poser C. M., Paty D. W., Scheinberg L., McDonald W. I., Davis F. A., Ebers G. C., Johnson K. P., Sibley W. A., Silberberg D. H., Tourtellotte W. W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 Mar;13(3):227–231. doi: 10.1002/ana.410130302. [DOI] [PubMed] [Google Scholar]
  9. Revesz T., Kidd D., Thompson A. J., Barnard R. O., McDonald W. I. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain. 1994 Aug;117(Pt 4):759–765. doi: 10.1093/brain/117.4.759. [DOI] [PubMed] [Google Scholar]
  10. Weinshenker B. G. Natural history of multiple sclerosis. Ann Neurol. 1994;36 (Suppl):S6–11. doi: 10.1002/ana.410360704. [DOI] [PubMed] [Google Scholar]
  11. Weinstock-Guttman B., Ransohoff R. M., Kinkel R. P., Rudick R. A. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol. 1995 Jan;37(1):7–15. doi: 10.1002/ana.410370105. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES